Paul Grayson
Director/Board Member bij SKYE BIOSCIENCE, INC.
Vermogen: 5 M $ op 29-02-2024
Profiel
Paul A.
Grayson is a businessperson who founded Fate Therapeutics, Inc. and Senomyx, Inc. and who has been the head of 8 different companies.
Presently, he occupies the position of President & Chief Executive Officer at Radionetics Oncology, Inc. and President & Chief Executive Officer of RuiYi, Inc. (China).
He is also on the board of Skye Bioscience, Inc. and Member of Aurora Biosciences Corp.
In the past he was President & Chief Executive Officer for Fate Therapeutics, Inc., President, Chief Executive Officer & Director at Tentarix Biotherapeutics, Inc., Managing Director at Sanderling Management CO LLC, Partner at Versant Venture Management LLC, Chairman for Naviscan, Inc., Chairman for CalciMedica, Inc. (US), President & Chief Executive Officer for Senomyx, Inc. and President, Chief Executive Officer & Director at Bird Rock Bio Sub, Inc.
He received an MBA from the University of California, Irvine and an undergraduate degree from the University of California, Los Angeles.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
SKYE BIOSCIENCE, INC.
2.81% | 29-02-2024 | 346 252 ( 2.81% ) | 5 M $ | 29-02-2024 |
Actieve functies van Paul Grayson
Bedrijven | Functie | Begin |
---|---|---|
SKYE BIOSCIENCE, INC. | Director/Board Member | 18-08-2023 |
Aurora Biosciences Corp.
Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Corporate Officer/Principal | 21-04-2010 |
RuiYi, Inc. (China)
RuiYi, Inc. (China) BiotechnologyHealth Technology Part of Bird Rock Bio, Inc., RuiYi, Inc. (China) develops biologic therapies. The private company is based in Pudong, China. The CEO of the Chinese company is Paul A. Grayson. RuiYi, Inc. (China was acquired by Bird Rock Bio, Inc. on March 22, 2012. | Chief Executive Officer | - |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company that focuses on discovering and developing novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology is based in Menlo Park, CA. The company spun out of Crinetics Pharmaceuticals in 2021 and is supported by Frazier Life Sciences, 5AM Ventures, Crinetics Pharmaceuticals, and GordonMD Investments. Radionetics is advancing a pipeline of novel small molecule radioligands targeting G-protein coupled receptors for the treatment of a broad range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. Nishan M. de Silva has been the CEO of the company since 2022. | Chief Executive Officer | 03-01-2024 |
Eerdere bekende functies van Paul Grayson
Bedrijven | Functie | Einde |
---|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Private Equity Investor | 01-01-2024 |
Pipeline Therapeutics, Inc.
Pipeline Therapeutics, Inc. BiotechnologyHealth Technology Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA. | Director/Board Member | 01-11-2023 |
Bird Rock Bio, Inc.
Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Chief Executive Officer | 18-08-2023 |
FATE THERAPEUTICS, INC. | Chief Executive Officer | 21-02-2011 |
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | Corporate Officer/Principal | 01-04-2008 |
Opleiding van Paul Grayson
University of California, Los Angeles | Undergraduate Degree |
University of California, Irvine | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
CHIMERIX, INC. | Health Technology |
FATE THERAPEUTICS, INC. | Health Technology |
SKYE BIOSCIENCE, INC. | Health Technology |
Bedrijven in privébezit | 16 |
---|---|
Aurora Biosciences Corp.
Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Health Technology |
Senomyx, Inc.
Senomyx, Inc. Food: Specialty/CandyConsumer Non-Durables Senomyx, Inc. engages in the development and commercialization of flavor ingredients for the packaged food, beverage, and ingredient supply industries. It develops high intensity sweeteners, savory flavors, bitter taste blockers, and cooling agents. The company was founded by Paul A. Grayson, Lubert Stryer, Yon Chien Tsien, Denis Baylor, Harold McGee, and Charles Zuker on September 16, 1998 and is headquartered in San Diego, CA. | Consumer Non-Durables |
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | Finance |
Naviscan, Inc.
Naviscan, Inc. Electronic Production EquipmentElectronic Technology Naviscan, Inc. develops, manufactures, and markets organ molecular imaging scanners. The company was founded by Irving Weinberg on January 31, 2006 and is headquartered in San Diego, CA. | Electronic Technology |
Ren Pharmaceuticals, Inc.
Ren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California. | Health Technology |
CalciMedica, Inc. (US)
CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | Health Technology |
Apoptos, Inc.
Apoptos, Inc. Pharmaceuticals: MajorHealth Technology Apoptos, Inc. discovers and develops small molecule anticancer drugs. The company focuses in drug therapies that directly induce tumor cell apoptosis. It was founded in 2007 and is headquartered in San Diego, CA | Health Technology |
Receptos LLC
Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
TempestTx, Inc.
TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Health Technology |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Bird Rock Bio, Inc.
Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Health Technology |
RuiYi, Inc. (China)
RuiYi, Inc. (China) BiotechnologyHealth Technology Part of Bird Rock Bio, Inc., RuiYi, Inc. (China) develops biologic therapies. The private company is based in Pudong, China. The CEO of the Chinese company is Paul A. Grayson. RuiYi, Inc. (China was acquired by Bird Rock Bio, Inc. on March 22, 2012. | Health Technology |
Progenitor Labs Ltd.
Progenitor Labs Ltd. Pharmaceuticals: MajorHealth Technology Progenitor Labs Ltd. develops drugs to regenerate specific tissues of the human body in response to injury, disease, and ageing. Its products include ProScreen and CombiCult. The company was founded by Yen Choo on February 12, 2010 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Pipeline Therapeutics, Inc.
Pipeline Therapeutics, Inc. BiotechnologyHealth Technology Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA. | Health Technology |
Tentarix Biotherapeutics, Inc. | |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company that focuses on discovering and developing novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology is based in Menlo Park, CA. The company spun out of Crinetics Pharmaceuticals in 2021 and is supported by Frazier Life Sciences, 5AM Ventures, Crinetics Pharmaceuticals, and GordonMD Investments. Radionetics is advancing a pipeline of novel small molecule radioligands targeting G-protein coupled receptors for the treatment of a broad range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. Nishan M. de Silva has been the CEO of the company since 2022. | Health Technology |